Journal of Clinical Oncology, Vol 25, No 6 (February 20), 2007: pp. 634-641
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.06.3081
A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu–Positive Breast Cancer
Allison W. Kurian,
Rebecca Newton Thompson,
Allison F. Gaw,
Sally Arai,
Rafael Ortiz,
Alan M. Garber
From the Department of Medicine, Division of Oncology; Department of Health Research and Policy, Division of Epidemiology; Department of Biological Sciences; Department of Medicine, Division of Bone Marrow Transplantation; Graduate School of Business; and the Veterans’ Affairs Palo Alto Health Care System and Center for Primary Care and Outcomes Research, Stanford University, Stanford, CA
Address reprint requests to Allison W. Kurian, MD, MSc, Division of Oncology, Stanford University School of Medicine, 875 Blake Wilbur Dr, Stanford, CA 94305-5820; e-mail: akurian{at}stanford.edu
PURPOSE: One-year adjuvant trastuzumab (AT) therapy, with or without anthracyclines, increases disease-free and overall survival in early-stage HER2/neu-positive breast cancer. We sought to evaluate the cost effectiveness of these regimens, which are expensive and potentially toxic.
METHODS: We used a Markov health-state transition model to simulate three adjuvant therapy options for a cohort of 49-year-old women with HER2/neu-positive early-stage breast cancer: conventional chemotherapy without trastuzumab; anthracycline-based AT regimens used in the National Surgical Adjuvant Breast and Bowel Project B-31 and North Central Cancer Treatment Group N9831 trials; and the nonanthracycline AT regimen used in the Breast Cancer International Research group 006 trial. The base case used treatment efficacy measures reported in the randomized clinical trials of AT. We measured health outcomes in quality-adjusted life-years (QALYs) and costs in 2005 United States dollars (US$) and subjected results to probabilistic sensitivity analysis.
RESULTS: In the base case, the anthracycline-based AT arm has an incremental cost-effectiveness ratio (ICER) of $39,982/QALY, whereas the nonanthracycline AT arm is more expensive and less effective; this result is insensitive to changes in recurrence rates, but if there is no benefit after 4 years, ICERs exceed $100,000/QALY for both AT arms. Results are moderately sensitive to variation in breast cancer survival rates and trastuzumab cost, and less sensitive to variations in cardiac toxicity.
CONCLUSION: AT has an ICER comparable to those for other widely used interventions. Longer clinical follow-up is warranted to evaluate the long-term efficacy and toxicity of different AT regimens.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
Related Editorial
- Do the Large Benefits Justify the Large Costs of Adjuvant Breast Cancer Trastuzumab?
Bruce E. Hillner and Thomas J. Smith
JCO 2007 25: 611-613
[Full Text]
Related Correspondence
- Health Economics in the Journal of Clinical Oncology and an Evaluation of the Indirect Costs and Benefits Associated With Adjuvant Trastuzumab
Gilberto de Lima Lopes, Jr and Stefan Gluck
JCO 2007 25: 3382-3383
[Full Text]
Related Article
- Health Economics in the Journal of Clinical Oncology and an Evaluation of the Indirect Costs and Benefits Associated With Adjuvant Trastuzumab
Gilberto de Lima Lopes, Jr and Stefan Gluck
JCO 2007 25: 3382-3383
[Full Text]
This article has been cited by other articles:
|
|
|
|
 
D. Lesniak, Y. Xu, J. Deschenes, R. Lai, J. Thoms, D. Murray, S. Gosh, J. R. Mackey, S. Sabri, and B. Abdulkarim
{beta}1-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer
Cancer Res.,
November 15, 2009;
69(22):
8620 - 8628.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Chan, H. W. Leung, C.-L. Lu, and S. J. Lin
Cost-Effectiveness of Trastuzumab as Adjuvant Therapy for Early Breast Cancer: A Systematic Review
Ann. Pharmacother.,
February 1, 2009;
43(2):
296 - 303.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Phillips
Closing the Evidence Gap in the Use of Emerging Testing Technologies in Clinical Practice
JAMA,
December 3, 2008;
300(21):
2542 - 2544.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-C. T. Shih and M. T. Halpern
Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean?
CA Cancer J Clin,
July 1, 2008;
58(4):
231 - 244.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. MacKenzie, S. Chapman, G. Salkeld, and S. Holding
Media influence on Herceptin subsidization in Australia: application of the rule of rescue?
J R Soc Med,
June 1, 2008;
101(6):
305 - 312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Lidgren, B. Jonsson, C. Rehnberg, N. Willking, and J. Bergh
Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer
Ann. Onc.,
March 1, 2008;
19(3):
487 - 495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. de Lima Lopes Jr and S. Gluck
Health Economics in the Journal of Clinical Oncology and an Evaluation of the Indirect Costs and Benefits Associated With Adjuvant Trastuzumab
J. Clin. Oncol.,
August 1, 2007;
25(22):
3382 - 3383.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Meropol and K. A. Schulman
In Reply
J. Clin. Oncol.,
August 1, 2007;
25(22):
3383 - 3383.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. E. Hillner and T. J. Smith
Do the Large Benefits Justify the Large Costs of Adjuvant Breast Cancer Trastuzumab?
J. Clin. Oncol.,
February 20, 2007;
25(6):
611 - 613.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. N. Levine, P. A. Ganz, and D. G. Haller
Economic Evaluation in the Journal of Clinical Oncology: Past, Present, and Future
J. Clin. Oncol.,
February 20, 2007;
25(6):
614 - 616.
[Full Text]
[PDF]
|
|
|
|
